Breast CancerFDA Approvals, News & Updates

Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation

In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
June 2019 Vol 5 No 3

In May 2019, the FDA approved Piqray (alpelisib; from Novartis) tablets, a PIK3CA inhibitor, in combination with Faslodex (fulvestrant; from AstraZeneca), an endocrine therapy, for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer and the genetic alteration, PIK3CA mutation, as detected by an FDA-approved test approved on the same day, the therascreen PIK3CA RGQ PCR Kit.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Piqray was based on a clinical trial with 572 postmenopausal women, and men, with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed during or after an endocrine-based therapy. In patients with a PIK3CA mutation, Piqray plus Faslodex treatment resulted in an average of 11 months without disease progression versus 5.7 months with Faslodex alone.

Some of the side effects associated with Piqray are elevated blood sugar, diarrhea, rash, nausea, fatigue, low red blood cell count, decreased appetite, inflammation in the mouth, vomiting, weight loss, low calcium levels, a rare blood-clotting disorder, and hair loss.

Recommended For You
Breast Cancer
Pink Ribbons in October
By Lillie D. Shockney, RN, BS, MAS, ONN-CG
Welcome to our newest issue of CONQUER. We know the value of hearing the experiences of cancer survivors and family caregivers. It helps people to relate, feel a sense of connection, and provides food for thought. We have many stories, with several focusing on breast cancer, including male breast cancer. Pink ribbons are not just for women.
Breast CancerSurvivorship
Listening to Our Instincts
By Teresa Todt
Cancer was the furthest thing from my mind, for many reasons. There was absolutely no family history of cancer. I was an avid fitness enthusiast. I tried to eat healthy, and the list goes on. And perhaps the most important reason for my peace of mind, a few months before my diagnosis, a mammogram and a follow-up appointment with my gynecologist gave me the “all clear” reassurance. Despite continued pain in my left breast, and sensitivity in the nipple, I was grateful that nothing was found.
Breast CancerPatient Stories
The Good, the Bad, and the Funny: Making the Most of a Life Shaped by Breast Cancer
By Lillie D. Shockney, RN, BS, MAS, ONN-CG
Enjoy Lillie Shockney’s sense of humor as you read her personal story of how working as a nurse and facing her own breast cancer diagnosis shaped her life and her lifelong work as a breast cancer educator and advocate.
Breast CancerImmunotherapy
A Breakthrough in the Treatment of Metastatic Triple-Negative Breast Cancer
By Erika Hamilton, MD
Recently, Tecentriq became the first immunotherapy to be approved for the treatment of patients with metastatic triple-negative breast cancer, a particularly difficult type of breast cancer.
Last modified: August 5, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.